Video

Dr. Jonasch on long-term efficacy and safety with belzutifan in renal cell carcinoma

In this video, Eric Jonasch, MD, discusses the results from 2022 ASCO Annual Meeting abstract 4509, “Phase 1 LITESPARK-001 (MK-6482-001) study of the HIF-2α inhibitor belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up.” Jonasch is a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

Related Videos
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.